Time：2026-03-19
(Shanghai, 18 March 2026) Medtide Inc. (03880.HK) announced that it has successfully stood out and been officially awarded the "Leading Enterprise" at the 2026 Forbes China Pioneers in Industry Development selection, co-initiated by Forbes China and Frost & Sullivan, a world-renowned growth consulting firm. This honor is a testament to Medtide Inc.’s profound industrial accumulation in the peptide field, global integrated service capabilities and innovative leadership, marking the high recognition of its professional strength and industrial value in the peptide CRDMO sector by authoritative institutions and the jury.
Against the backdrop of the in-depth integration of the scientific and technological revolution and industrial transformation, this selection takes promoting the high-quality development of the industry as its core proposition, focusing on key sectors such as AI, healthcare, new energy and manufacturing.Through multiple rounds of professional screening and comprehensive evaluation, it systematically identifies pioneering players in each track with outstanding innovation capabilities, development resilience and ecological construction capacity. Aiming to convey the value orientation of long-termism and encourage enterprises to stay focused amid changes and reshape their development paths in the face of challenges, Medtide Inc.’s emergence as a winner among numerous participating enterprises is the industry’s full recognition of its achievements in deepening layout in the track and making continuous innovative breakthroughs, as well as an authoritative certification of its contributions and leading value to the industry.
Dr. Shawn Lee, Co-founder and Executive Director of Medtide Inc.
Medtide Inc. was awarded the title of "2026 Forbes China Leading Enterprise in Industry Development".
Being listed on the 2026 Forbes China Pioneers in Industry Development Leading Enterprise list and receiving the award on site is not only a significant honor in Medtide Inc.’s development journey, but also a new driving force for its continuous in-depth development in the future. Going forward, Medtide Inc. will continue to adhere to the innovation-driven development philosophy, further consolidate its technological advantages, improve its global service network and industrial layout, empower global pharmaceutical innovation with higher-quality professional services, and boost the high-quality development of the healthcare industry. The company will earnestly fulfill the responsibilities and missions of a leading enterprise in the industry, and contribute core strength to building a more resilient and vibrant industrial ecosystem.
About Medtide Inc.
Medtide Inc. (03880.HK) is a peptide-focused Contract Research, Development and Manufacturing Organization (CRDMO), providing full-cycle services ranging from early discovery, preclinical and clinical development to commercial manufacturing. Headquartered in Hangzhou, China, the company has commercial manufacturing bases and offices in both China and the United States. With 25years of deep cultivation in the peptide field, Medtide Inc. is a CRDMO with global operation and integrated service capabilities.
We offer CRDMO services covering the entire life cycle of pharmaceutical R&D, including the discovery and synthesis of New Chemical Entities (NCEs),as well as the development and commercial manufacturing of Chemistry,Manufacturing and Controls (CMC). Since its establishment, Medtide Inc. has provided peptide drug synthesis, development, manufacturing and CMC application support services complying with the regulatory requirements of major global markets for more than 1,000 customers worldwide, with projects covering over 50 countries and regions, including major markets such as China, the United States, Japan, Europe, South Korea and Australia.
As a reliable and sustainable enterprise, Medtide Inc. has established long-term partnerships with many customers. Through close cooperation, the company helps customers bring pharmaceuticals that have a profound impact on human health to the market. Centering on patients, we are committed to improving patients’ quality of life and advancing the development of the global human health cause.
